Rigel Pharmaceuticals Grants Stock Awards to Employees
Rigel Pharmaceuticals announced it has granted restricted stock units to 18 non-executive employees under its inducement plan. The awards are intended as material incentives for new hires.
South San Francisco, Calif. – Rigel Pharmaceuticals (Nasdaq: RIGL) announced on October 2, 2026, that it has granted awards under its Inducement Plan. The grants were approved by the Compensation Committee of Rigel's Board of Directors.
Specifically, the company awarded 35,275 restricted stock units to 18 non-executive employees. These awards are designed as material inducements for employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). The stock units vest over a four-year period, with 25% vesting each year.
Rigel Pharmaceuticals is a biotechnology company focused on developing therapies for hematologic disorders and cancer. Founded in 1996 and based in South San Francisco, the company aims to discover and commercialize novel treatments that improve patient outcomes.
The company did not provide further details on the specific value or recipients of the awards. Rigel's stock is publicly traded on the Nasdaq under the ticker symbol RIGL.